Actelion won't exercise option to buy Trophos

By Anita Greil ZURICH (MarketWatch) — Actelion AG said Tuesday it wouldn't exercise an option to acquire Trophos SA, a privately held French pharmaceutical company, after an experimental drug for the treatment of Lou Gehrig's disease failed in a …
See all stories on this topic »